Display options
Cite
Dobbins DE. Neuropeptide modulation of lymphatic smooth muscle tone in the canine forelimb. Mediators Inflamm. 1992;1(4):241-6doi: 10.1155/S096293519200036X.
Dobbins, D. E. (1992). Neuropeptide modulation of lymphatic smooth muscle tone in the canine forelimb. Mediators of inflammation, 1(4), 241-6. https://doi.org/10.1155/S096293519200036X
Dobbins, D E. "Neuropeptide modulation of lymphatic smooth muscle tone in the canine forelimb." Mediators of inflammation vol. 1,4 (1992): 241-6. doi: https://doi.org/10.1155/S096293519200036X
Dobbins DE. Neuropeptide modulation of lymphatic smooth muscle tone in the canine forelimb. Mediators Inflamm. 1992;1(4):241-6. doi: 10.1155/S096293519200036X. PMID: 18475467; PMCID: PMC2365347.
Copy Download .nbib Format: NLM
Share it on

Mediators Inflamm. 1992;1(4):241-6. doi: 10.1155/S096293519200036X.

Neuropeptide modulation of lymphatic smooth muscle tone in the canine forelimb.

Mediators of inflammation

D E Dobbins

Affiliations

  1. Department of Physiology Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda MD 20814-4799 USA.

PMID: 18475467 PMCID: PMC2365347 DOI: 10.1155/S096293519200036X

Abstract

Neurokinin A and B are putative inflammatory mediators. We assessed their ability to alter prenodal lymphatic resistance. Intralymphatic neurokinin A (3.0 x 10(-6), 3.0 x 10(-5) and 3.0 x 10(-4) mol l(-1)) significantly constricted lymphatics at the two highest doses. Preliminary experiments suggested that neurokinin B might dilate lymphatics. To test this, lymphatic pressure was increased by norepinephrine (3.1 x 10(-6) mol l(-1)). Neurokinin B (2.7 x 10(-4) mol l(-1)) was then infused intralymphatically during norepinephrine infusion. Norepinephrine increased perfusion pressure from 5.6 +/- 0.6 mmHg to 12.1 +/- 1.4 mmHg. Subsequent infusion of neurokinin B significantly decreased lymphatic perfusion pressure from 11.9 +/- 1.3 mmHg to 9.9 +/- 1.1 mmHg. These data indicate that neurokinin A and B can alter lymphatic resistance and are consistent with the hypothesis that lymph vessel function may be subject to modulation by neurokinins.

References

  1. Eur J Pharmacol. 1985 Aug 7;114(1):61-6 - PubMed
  2. Am Rev Respir Dis. 1990 Nov;142(5):1119-23 - PubMed
  3. J Neuropathol Exp Neurol. 1987 Sep;46(5):567-84 - PubMed
  4. Annu Rev Med. 1987;38:143-8 - PubMed
  5. Circulation. 1988 Feb;77(2):264-9 - PubMed
  6. Am J Physiol. 1988 Sep;255(3 Pt 2):H514-24 - PubMed
  7. Annu Rev Neurosci. 1988;11:13-28 - PubMed
  8. Br J Pharmacol. 1987 Dec;92(4):781-8 - PubMed
  9. Am Rev Respir Dis. 1987 Sep;136(3):718-21 - PubMed
  10. Microcirc Endothelium Lymphatics. 1990 Aug-Oct;6(4-5):253-66 - PubMed
  11. Am J Physiol. 1991 Jan;260(1 Pt 2):H1-5 - PubMed
  12. Microcirc Endothelium Lymphatics. 1990 Dec;6(6):409-25 - PubMed
  13. Agents Actions. 1988 Feb;23(1-2):14-5 - PubMed
  14. Arch Histol Cytol. 1991 Jul;54(3):311-20 - PubMed
  15. N Engl J Med. 1986 May 15;314(20):1323 - PubMed
  16. Regul Pept. 1991 Jul 23;35(1):81-91 - PubMed
  17. Arch Histol Cytol. 1991 May;54(2):241-8 - PubMed
  18. Arch Histol Cytol. 1990;53 Suppl:199-208 - PubMed
  19. Biochem Biophys Res Commun. 1983 Jul 29;114(2):533-40 - PubMed

Publication Types